Pleiotropic effects of antiarrhythmic agents: Dronedarone in the treatment of atrial fibrillation

Clinical Medicine Insights: Cardiology

Volumn 7, Issue , 2013, Pages 127-140

  Heijman, Jordi ^a   Heusch, Gerd ^a   Dobrev, Dobromir ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Dronedarone; Pleiotropic effects

Indexed keywords

AMIODARONE; DRONEDARONE; G PROTEIN COUPLED RECEPTOR; IVABRADINE; PLACEBO; RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

ACTION POTENTIAL; ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CALCIUM TRANSPORT; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; EYE DISEASE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RHYTHM; HUMAN; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; MORBIDITY; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN PHOSPHORYLATION; QT PROLONGATION; REPOLARIZATION; REVIEW; SINUS RHYTHM; SKIN DISEASE; THYROID DISEASE; VASODILATATION; VOMITING;

EID: 84881492641     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S8445     Document Type: Review

References (80)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-245.
2. Chinitz JS, Halperin JL, Reddy VY, Fuster V. Rate or rhythm control for atrial fibrillation: update and controversies. Am J Med. 2012;125(11):1049-56.
3. Camm AJ, Al-Khatib SM, Calkins H, et al. A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J. 2012;164(3):292-302. e291.
4. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375(9721):1212-23.
5. Dobrev D. Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice. Expert Opin Pharmacother. 2011;12(8):1195-9.
6. Dobrev D, Carlsson L, Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov. 2012;11(4):275-91.
7. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. Int J Cardiol. 2012;155(3):362-71.
8. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-9.
9. Schrickel JW, Schwab JO, Yang A, Bitzen A, Luderitz B, Lewalter T. "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, β-blockers, and digitalis. Pacing Clin Electrophysiol. 2006;29(4):363-6.
10. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009;120(7):636-44.
11. Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009;2(5):588-97.
12. Naccarelli GV. Appropriate and inappropriate use of dronedarone in 2013. Curr Treat Options Cardiovasc Med. 2013;15(4):467-75.
13. Camm AJ, Savelieva I. Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance. Heart. 2013. [Epub ahead of print.]
14. Podda GM, Casazza G, Casella F, Dipaola F, Scannella E, Tagliabue L. Addressing the management of atrial fibrillation-a systematic review of the role of dronedarone. Int J Gen Med. 2012;5:465-78.
15. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481-7.
16. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10): 987-99.
17. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(3):527. e521-9.
18. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25): 2678-87.
19. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7): 668-78.
20. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATH ENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/ atrial flutter. Circulation. 2009;120(13):1174-80.
21. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605.
22. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76.
23. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18): 2516-25.
24. Ezekowitz MD, DiMarco J, Kaszala K, Ellenbogen K, Boddy A, Koren A. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone on atrial fibrillation burden in subjects with permanent pacemakers (HESTIA). Circulation. 2012;126:A15020 (Abstract).
25. Verrier RL, Pagotto VP, Kanas AF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm. 2013;10(1):121-7.
26. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56(15):1216-24.
27. Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol. 2013;9(1):71-88.
28. Heijman J, Dobrev D. Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(7): 571-4.
29. 2 P) channels. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(10):1003-16.
30. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8): 2955-68.
31. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104(22):2722-7.
32. Bauman JL. Torsade de pointes due to dronedarone: deja vu? Pharmacotherapy. 2012;32(8):764-6.
33. Varro A, Takacs J, Nemeth M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001;133(5):625-34.
34. K,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697-706.
35. Pandit SV, Berenfeld O, Anumonwo JM, et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J. 2005;88(6):3806-21.
36. K,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(3):251-9.
37. Milnes JT, Madge DJ, Ford JW. New pharmacological approaches to atrial fibrillation. Drug Discov Today. 2012;17(13-14):654-9.
38. Tsuji Y, Heijman J, Nattel S, Dobrev D. Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol. 2013; 108(2):336.
39. Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33(15):1870-7.
40. + exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059-70.
41. + model: sinus rhythm and chronic atrial fibrillation. Circ Res. 2011;109(9): 1055-66.
42. Heijman J, Voigt N, Nattel S, Dobrev D. Calcium handling and atrial fibrillation. Wien Med Wochenschr. 2012;162(13-14):287-91.
43. Dobrev D. Electrical remodeling in atrial fibrillation. Herz.2006;31(2):108-112;quiz 142-103.
44. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1): 62-73.
45. Zhang YH, Sun HY, Chen KH, et al. Evidence for functional expression of TRPM7 channels in human atrial myocytes. Basic Res Cardiol. 2012;107(5):282.
46. Harada M, Luo X, Qi XY, et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation. 2012;126(17):2051-64.
47. Ehrlich JR, Dobrev D. Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol. 2011;384(2):109-14.
48. Heusch G, Schulz R. Pleiotropic effects of dronedarone on ischemia/ reperfusion injury in heart and brain. Cardiovasc Drugs Ther. 2012;26(3): 257-63.
49. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589-601.
50. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56(24):1973-83.
51. Heusch G, Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflugers Arch. 1983;397(4):284-9.
52. f current is the primary mechanism responsible for its bradycardic effect. J Cardiovasc Electrophysiol. 2013.
53. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16.
54. Heusch G. A BEAUTIFUL lesson-ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J. 2009;30(19):2300-1.
55. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279(1):25-32. 56. Heusch G. Alpha-adrenergic mechanisms in myocardial ischemia. Circulation. 1990;81(1):1-13.
56. Heusch G, Baumgart DCamici P,et al., alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101(6): 689-94.
57. Grossman M, Dobrev D, Kirch W. Amiodarone causes endotheliumdependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther. 1998;64(3):302-11.
58. Himmel HM, Dobrev D, Grossmann M, Ravens U. N-desethylamiodarone modulates intracellular calcium concentration in endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(6):489-96.
59. Skyschally A, Heusch G. Reduction of myocardial infarct size by dronedarone in pigs-a pleiotropic action? Cardiovasc Drugs Ther. 2011;25(3): 197-201.
60. Bukowska A, Hammwohner M, Sixdorf A, et al. Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol. 2012;166(3):964-80.
61. Mourouzis I, Kostakou E, Galanopoulos G, Mantzouratou P, Pantos C. Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice. Mol Cell Biochem. 2013.
62. Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med. 2002;162(12):1388-94.
63. Chen WJ, Yeh YH, Lin KH, Chang GJ, Kuo CT. Molecular characterization of thyroid hormone-inhibited atrial L-type calcium channel expression: implication for atrial fibrillation in hyperthyroidism. Basic Res Cardiol. 2011;106(2):163-74.
64. Nishida K, Qi XY, Wakili R, et al. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation. 2011;123(2):137-46.
65. Dagres N, Varounis C, Iliodromitis EK, Lekakis JP, Rallidis LS, Anastasiou-Nana M. Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2011;11(6): 395-400.
66. Nattel S. Dronedarone in atrial fibrillation-Jekyll and Hyde? N Engl J Med. 2011;365(24):2321-2.
67. Breitenstein A, Sluka SH, Akhmedov A, et al. Dronedarone reduces arterial thrombus formation. Basic Res Cardiol. 2012;107(6):302.
68. Engelhorn T, Schwarz MA, Heusch G, Doerfler A, Schulz R. Reduction of cerebral infarct size by dronedarone. Cardiovasc Drugs Ther. 2011;25(6): 523-9.
69. Naccarelli GV, Wolbrette DL, Levin V, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011;5:103-19.
70. Camm AJ, Lip GYDe Caterina R,et al, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-413.
71. Benaim G, Paniz Mondolfi AE. The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol. 2012;9(10):605-9.
72. Benaim G, Hernandez-Rodriguez V, Mujica-Gonzalez S, et al. In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother. 2012;56(7):3720-5.
73. Said SM, Esperer HD, Kluba K, et al. Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). Int J Cardiol. 2012. [Epub ahead of print.]
74. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol. 2012;110(4):607-13.
75. Marinelli A, Capucci A. Antiarrhythmic drugs for atrial fibrillation. Expert Opin Pharmacother. 2011;12(8):1201-15.
76. Lin L, Bai R. Dronedarone: is it time to turn it down? Expert Opin Drug Saf. 2013;12(1):5-8.
77. Mullard A. Second chance for dronedarone after recent setback? Lancet. 2012;379(9816):601.
78. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/ AHA/HRS Recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;127(18):1916-26.
79. Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol. 2012;60(6):539-45.
80. Jamshidi Y, Nolte IM, Dalageorgou C, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol. 2012;60(9):841-50.